TEVA - Teva Pharmaceutical Lifts Revenue Forecast - Huntington's And Migraine Drugs Help Q3 Performance | Benzinga
Teva Pharmaceutical Industries Ltd (NYSE: TEVA) reported Q3 sales of $3.85 billion, beating the consensus of $3.72 billion.
The 7% Y/Y increase was mainly due to higher revenues from generic products in all segments, Austedo (Huntington's Disease treatment) in the North America segment and Ajovy (migraine drug) in all segments, partially offset by lower revenues from Bendeka and Treanda in the North America segment as well as from API sales to third parties.
The company reported Q3 adjusted EPS of $0.60, ...